Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

40 citing papers in PubMed, 92 citations in OpenAlex.

1. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
   Trial
2. Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.Journal of translational medicine · 2014
   Trial
3. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2010
   Trial
4. From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.Frontiers in immunology · 2026
   Review
5. Hemocyanins: Microscopic Giants with Unique Structural Features for Applications in Biomedicine.Vaccines · 2025
   Review
6. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma.Scientific reports · 2021
   Article
7. Therapeutic vaccines for aggressive B-cell lymphoma.Leukemia & lymphoma · 2020
   Article
8. Neoantigens in Hematologic Malignancies.Frontiers in immunology · 2020
   Review
9. Immune Response Regulation by Antigen Receptors' Clone-Specific Nonself Parts.Frontiers in immunology · 2018
   Review
10. Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.Frontiers in immunology · 2017
    Review
11. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015
    Review
12. Haematological malignancies: at the forefront of immunotherapeutic innovation.Nature reviews. Cancer · 2015
    Review
13. Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.BioMed research international · 2015
    Article
14. Anti-cancer vaccines - a one-hit wonder?The Yale journal of biology and medicine · 2014
    Review
15. Peptide vaccines for hematological malignancies: a missed promise?International journal of hematology · 2014
    Review
16. Antigen-specific vaccines for cancer treatment.Human vaccines & immunotherapeutics · 2014
    Review
17. DNA vaccine for cancer immunotherapy.Human vaccines & immunotherapeutics · 2014
    Review
18. Therapeutic cancer vaccines.Advances in cancer research · 2014
    Review
19. Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model.Journal of translational medicine · 2013
    Article
20. CD28 aptamers as powerful immune response modulators.Molecular therapy. Nucleic acids · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as